Back to top

Analyst Blog

Actelion (ALIOF) recently announced that data on pipeline candidate Opsumit from a pivotal phase III study, SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome), was published in the New England Journal of Medicine.

We note that Actelion is evaluating Opsumit for the treatment of patients suffering from pulmonary arterial hypertension (PAH).

The results from the trial (n=742) showed that the risk of a morbidity/mortality event was cut by 45% in patients who were administered Opsumit as compared to those on placebo.

Moreover, Opsumit was able to significantly reduce the risk of morbidity/mortality in both treatment-naïve and treatment-experienced patients.

We remind investors that Opsumit is currently under review in the U.S. and EU.

Apart from PAH, Opsumit is also being evaluated in a pivotal phase III program in patients suffering from digital ulcers associated with systemic sclerosis. Results from this study are expected in 2014. In addition, Opsumit is being evaluated for the treatment of glioblastoma (phase I).

Meanwhile, Actelion has another candidate, selexipag, which is being evaluated for the treatment of PAH in a phase III study, GRIPHON. Results are expected in 2014.

We believe that the successful development and commercialization of Opsumit and selexipag will further strengthen Actelion’s PAH franchise which currently boasts of three drugs, Tracleer, Ventavis and Veletri.

Actelion currently carries a Zacks Rank #1 (Strong Buy). Other stocks that look attractive include Biogen Idec Inc. (BIIB - Analyst Report), Gilead Sciences Inc. (GILD - Analyst Report) and Affymetrix Inc. (AFFX - Analyst Report). All three carry a Zacks Rank #1.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%